Kayyem Jon Faiz
Director · Inhibrx Biosciences, Inc.
Every open-market stock purchase Kayyem Jon Faiz has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- INBXInhibrx Biosciences, Inc.
14 purchases totalling $9.0M at an average of $19.33 per share. See all insider buying in INBX →
Avg price paid$19.33Latest price—Market capUnknown
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
| Date | Ticker | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Sep 23, 2026 | INBXcluster | 5,000 | $100.00 | $500.0K | SEC ↗ |
| Sep 16, 2026 | INBXcluster | 5,000 | $100.00 | $500.0K | SEC ↗ |
| Sep 8, 2026 | INBXcluster | 5,000 | $113.52 | $567.6K | SEC ↗ |
| Nov 20, 2024 | 18,750 | $14.19 | $266.1K | SEC ↗ | |
| Nov 20, 2024 | 18,750 | $14.19 | $266.1K | SEC ↗ | |
| Nov 19, 2024 | 34,843 | $14.23 | $495.8K | SEC ↗ | |
| Nov 19, 2024 | 34,843 | $14.23 | $495.8K | SEC ↗ | |
| Jun 5, 2024 | 49,284 | $17.23 | $849.2K | SEC ↗ | |
| Jun 5, 2024 | 8,265 | $17.89 | $147.9K | SEC ↗ | |
| Jun 4, 2024 | 23,726 | $18.24 | $432.8K | SEC ↗ | |
| Jun 4, 2024 | 65,337 | $17.44 | $1.1M | SEC ↗ | |
| Jun 3, 2024 | 46,792 | $16.61 | $777.2K | SEC ↗ | |
| Jun 3, 2024 | 80,738 | $17.90 | $1.4M | SEC ↗ | |
| May 31, 2024 | 70,193 | $16.14 | $1.1M | SEC ↗ |
Follow new qualifying clusters involving Kayyem Jon Faiz or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Kayyem Jon Faiz's Form 4 filings on SEC EDGAR (CIK 1366268) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.